Xenetic Biosciences (XBIO) Income from Continuing Operations (2011 - 2026)
Xenetic Biosciences' (XBIO) quarterly Income from Continuing Operations came in at 40356361.0 in Q1 2026, up 4.6% YoY from 38580813.71 in Q1 2025, and down 6377.47% on a QoQ basis from 623027.0 in Q4 2025.
Xenetic Biosciences (XBIO) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Xenetic Biosciences (XBIO) has 16 years of Income from Continuing Operations data on file, last reported at 40356361.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 4.6% year-over-year to 40356361.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 125548534.0 (up 0.55% YoY) and the FY2025 annual result came in at 42634582.0, up 5.95% from the prior year.
- Income from Continuing Operations fell to 40356361.0 in Q1 2026, from 623027.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 623027.0 in Q4 2025 to a low of 42324412.0 in Q2 2025.
- A 5-year average of 30500991.0 and a median of 40198188.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 2390.81% — and 2025, when it surged 43.32%.
- Tracing XBIO's Income from Continuing Operations over 5 years: stood at 1590371.0 in 2022, then grew by 21.05% to 1255667.0 in 2023, then rose by 12.47% to 1099145.0 in 2024, then surged by 43.32% to 623027.0 in 2025, then tumbled by 6377.47% to 40356361.0 in 2026.
- The last three Income from Continuing Operations figures came in at 40356361.0 (Q1 2026), 623027.0 (Q4 2025), and 42244734.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Xenetic Biosciences | 8.01 Mn | 1.54 Mn | - | -929,623.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -41.13 Mn |
| Mar 31, 2026 | -40.36 Mn |
| Dec 31, 2025 | -623,027.00 |
| Sep 30, 2025 | -42.24 Mn |
| Jun 30, 2025 | -42.32 Mn |
| Mar 31, 2025 | -42.30 Mn |
| Dec 31, 2024 | -1.10 Mn |
| Sep 30, 2024 | -41.10 Mn |
| Jun 30, 2024 | -41.74 Mn |
| Mar 31, 2024 | -41.37 Mn |
| Dec 31, 2023 | -1.26 Mn |
| Sep 30, 2023 | -40.35 Mn |
| Jun 30, 2023 | -40.20 Mn |
| Mar 31, 2023 | -39.62 Mn |
| Dec 31, 2022 | -1.59 Mn |
| Sep 30, 2022 | -33.65 Mn |
| Jun 30, 2022 | -35.29 Mn |
| Mar 31, 2022 | -33.42 Mn |
| Dec 31, 2021 | -1.88 Mn |
| Sep 30, 2021 | -1.35 Mn |